Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study

BACKGROUND: Radium-223 dichloride (radium-223), a first-in-class α-emitting radiopharmaceutical, is recommended in both pre- and post-docetaxel settings in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases based on overall survival benefit demonstrated in the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Nilsson, S., Cislo, P., Sartor, O., Vogelzang, N. J., Coleman, R. E., O'Sullivan, J. M., Reuning-Scherer, J., Shan, M., Zhan, L., Parker, C.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4843190/
https://ncbi.nlm.nih.gov/pubmed/26912557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw065
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados